Risk Adapted Therapy: 11677 Clinical Trials, Page 1 of 1168

1 2 3 4 5 10 15 20  Last Page »

Hide Studies Not Open or Pending

4

Risk-adapted Therapy in HPV+ Oropharyngeal Cancer Using Circulating Tumor (ct)HPV DNA Profile – The ReACT Study

Condition(s):HPV-Associated Oropharyngeal Squamous Cell Carcinoma; HPV Positive Oropharyngeal Squamous Cell Carcinoma; HPV-Mediated (P16-Positive) Oropharyngeal Carcinoma by AJCC V8 Stage; HPV-Related Squamous Cell Carcinoma; Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8; Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8; Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8; Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8; Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8; Pathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8; HPV-Mediated (P16-Positive) Oropharyngeal Carcinoma by AJCC V8 Clinical Stage; HPV-Mediated (P16-Positive) Oropharyngeal Carcinoma by AJCC V8 Pathologic StageLast Updated:July 11, 2023Recruiting

1 2 3 4 5 10 15 20  Last Page »

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.